In a regulatory filing, Vertex Pharmaceuticals (VRTX) noted that on December 8, the U.S. Food and Drug Administration approved Casgevy, an autologous genome edited hematopoietic stem cell-based gene therapy indicated for the treatment of sickle cell disease in people 12 years and older with recurrent vaso-occlusive crises. “We have established a wholesale acquisition cost for CASGEVY in the United States of $2.2 million,” the filing stated. Crispr Therapeutics (CRSP) is a partner with Vertex on Casgevy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Needham biotechnology analyst to hold an analyst/industry conference call
- MaxCyte price target raised to $10 from $7 at BTIG
- Vertex says Health Canada grants expanded use of Kalydeco
- Vertex announces EMA validation for marketing authorization of KAFTRIO
- Vertex Pharmaceuticals announces EC approval of KAFTRIO/ivacaftor combination